Related Experiment Video
Updated: Mar 24, 2026
Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
Effects of Arnica comp.-Heel® on reducing cardiovascular events in patients with stable coronary disease
Massimo Fioranelli1, Maria Bianchi, Maria G Roccia
1G. Marconi University, Rome, Italy - massimo.fioranelli@gmail.com.
Insights
Adding Arnica comp.-Heel® to standard therapy significantly reduced cardiovascular events in stable coronary artery disease patients. This anti-inflammatory treatment shows promise for secondary prevention, lowering event rates effectively.
Area of Science:
- Cardiology
- Pharmacology
- Inflammation Research
Background:
- Atherosclerotic plaques in stable coronary artery disease (CAD) feature inflammatory cells.
- Inhibiting inflammation may reduce plaque instability and cardiovascular events.
- Arnica comp.-Heel® is a low-dose, multi-component medication with anti-inflammatory properties.
Purpose of the Study:
- To assess the efficacy of daily Arnica comp.-Heel® tablets in reducing cardiovascular events in stable CAD patients.
- To investigate the anti-inflammatory potential of Arnica comp.-Heel® in cardiovascular disease secondary prevention.
Main Methods:
- Retrospective observational study of 44 stable CAD patients.
- Group 1 (n=25): Standard therapy (aspirin/clopidogrel + statins).
- Group 2 (n=18): Standard therapy + Arnica comp.-Heel® (1 tablet/day).
- Primary outcome: Incidence of acute coronary syndrome, out-of-hospital cardiac arrest, or ischemic stroke.
Main Results:
- One cardiovascular event (5.6%) in the Arnica comp.-Heel® group.
- Four cardiovascular events (16%) in the standard therapy group.
- A notable reduction in cardiovascular events with the addition of Arnica comp.-Heel®.
Conclusions:
- Arnica comp.-Heel® (1 tablet/day) combined with standard therapies is effective for secondary prevention in stable CAD.
- The treatment reduces the incidence of cardiovascular events in patients with stable coronary artery disease.
- Anti-inflammatory treatment with Arnica comp.-Heel® may improve clinical outcomes in stable CAD.
Background:
The purpose of the study was to evaluate the effectiveness of the treatment with one tablet a day of a low dose multicomponent medication (Arnica comp.-Heel® tablets) with anti-inflammatory properties in order to reduce the risk of cardiovascular events in patients with clinically stable coronary disease. The presence of inflammatory cells in atherosclerotic plaques of patients with stable coronary disease indicates the possibility to act by inhibiting the inflammatory phenomenon with Arnica comp.-Heel® tablets reducing the risk of instability of the plaque and, consequently, improving the clinical outcome in patients with stable coronary disease.
Methods:
Within this retrospective observational spontaneous clinical study 44 patients (31 males and 13 females) all presenting stable coronary artery disease were evaluated; 25 subjects were treated with only acetylsalicylic acid and/or clopidogrel in association with statins (standard therapeutic protocol) while for the other 18 subjects the standard therapeutic protocol was integrated with Arnica comp.-Heel® (one sublingual tablet/day). The primary outcome was to evaluate the incidence of acute coronary syndrome, out-of-hospital cardiac arrest, or non-cardioembolic ischemic stroke.
Results:
The evaluation of the primary outcome showed that in the group of patients (18) who received the standard therapeutic protocol plus Arnica comp.-Heel® only one cardiovascular event was registered (5.6%) while in the group treated only with standard therapy 4 events were recorded in 25 patients (16%).
Conclusions:
The treatment with Arnica comp.-Heel® (one tablet/day) in combination with standard therapies for secondary prevention is effective in reducing the incidence of cardiovascular events in patients with stable coronary artery disease.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:20Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:26Atherosclerosis III: Management
01:21Rheumatic Heart Disease III: Medical Management